The Pratilas lab showed that SHP2 inhibitors act synergistically with MEK inhibitors [21] and more so with CDK4/6 inhibitors [23] to suppress MPNST growth. This evidence concerns the gene CDK4 and malignant peripheral nerve sheath tumor.